36 results about "Localized fat" patented technology

The present invention concerns a method and a kit, for the treatment of a selected area of the skin and / or subcutaneous tissue, and in particular for the cosmetic treatment of skin conditions such as regional fat deposits including cellulite. The method comprises heating the selected area to a sustained skin temperature of about 32 to about 50° C. for a desired period of time, using a device comprising either a heat source capable of conductively heating the selected area or, alternatively, an infra-red source for emitting infra-red with a wavelength from about 700 nm to about 15000 nm. The method also comprises administering, simultaneously or sequentially in either order, a composition containing an active agent selected from the group comprising a skin active, a nutrient absorption suppressant or a thermogenic agent, preferably a metabolic stimulating agent, more preferably a lipolytic agent, or a mixture thereof, the composition being either a topical composition for application to the selected area, or an area adjacent thereto, or an oral composition.

Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.

Compositions and methods useful in the reduction of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.

Compositions and methods useful in the non-surgical removal of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion agents and pharmaceutically acceptable excipients but do not contain phosphotidylcholine. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.

Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.

The present invention aims to provide reduction of localized fat, particularly for the treatment, prevention or alleviation of gynoid lypodystrophy.The cosmetic composition of the invention comprises:(a) from 4.0 to 27.0% by weight of active ingredients comprising:(i) at least one localized fat reducing agent selected from the group consisting of natural, modified and synthetic substances,(ii) at least one alkaloid,(iii) at least one oil or vegetable extract,(iv) at least one antioxidant, and(v) at least one film forming agent;(b) 6.0 to 32.0% by weight of cosmetically acceptable additives; and(c) q.s.p. 100% by weight of hydrophilic gel-cream base.The invention also comprises a gel-cream formulation for localized fat reduction, as well as the use of said composition or formulation for manufacturing of a cosmetic for the treatment, prevention or alleviation of gynoid lypodystrophy.

The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.

A non-invasive method of enhancing the permeability of the skin to a biologically active permeant or compound is described utilizing a combination of sonophoresis and chemical enhancers. Synergism brought simultaneously applying iontophoresis, electroporation, mechanical vibrations and magnetophoresis is used to optimize the transcutaneous active permeation of compounds, considerably lowering the time of treatment.The method is intended also for, among others, the non-invasive painless treatment of cellulitis, localized fat stretch marks and flacid skin.

A composition for displacing loose skin and removing subcutaneous deposits of fatty tissue. The composition includes effective amounts of one or more bleomycin-type drugs that are operative to cause apoptosis in localized fat cells, thus causing permanent eradication of such cells. Loose skin is likewise displaced with dense fibrous tissue produced via selective scarring induced by the active bleomycin-type drugs. The compositions are formulated as creams, lotions, gels, waxes, foams, sprays and the like for selectively applied, local topical application, and may also be administered as a conventional transdermal patch. The compositions may alternatively be formulated to be injected into the skin.

The present invention provides a pharmaceutical composition for reducing localized fat, comprising a pharmaceutically acceptable aqueous solution, drug-containing micelles made of surfactants, and resveratrol encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high fat tissue bioavailability, few side effects, and sustained release.

The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

The present invention relates to an injectable composition for removing local fat comprising 300 to 600 IU of hyaluronidase and, based on the weight of the total composition, 0.08 to 0.4% by weight oflocal anesthetic, 0.01 to 0.02% by weight of antihistamine, 0.01 to 4.0% by weight of lipolysis stimulator, 0.01 to 0.08% by weight of the neurotransmitter, 0.01 to 4.0% by weight of the lipolytic agent, 0.05 to 0.3% by weight of reagent for pH adjustment and as allergies and acidosis treatment, and 0.1 to 2.0% by weight of collagen production stimulator, with the remainder being saline solution.According to the present invention, reduction in local fat tissues is promoted to ameliorate obesity and keep weight loss and a body shape. In addition, side effects or imbalance in skin can be prevented by evenly removing fat, and generation of collagen is promoted to give an effect of lifting where skin elasticity is kept.

The present invention provides a composition for lipolysis, for example a pharmaceutical composition for preventing or treating obesity including localized fat deposits (LFD), comprising certain phosphocholine derivatives or pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention shows an excellent lipolytic activity as well as a uniform lipolytic activity. And also, the pharmaceutical composition of the present invention can minimize side effects such as inflammation, tissue necrosis, etc., at the administered site. In addition, the pharmaceutical composition of the present invention has excellent storage stability.

The present invention provides a fat-soluble injection. A main component of the fat-soluble injection is alisol A. The fat-soluble injection acts on sites where local fat accumulates. For the first time, the alisol A is proposed to be injected directly into subcutaneous fat and used as the fat-soluble injection. Compared with fat-soluble injection on the market, the fat-soluble injection is saferand less in side effects. Compared with traditional liposuction surgery, patients are less in pains, risks are lower, operations are simple, recovery after surgery is quick, and the fat-soluble injection has unparalleled advantages in a local obesity treatment.

The present invention is related to a cosmetic method for promoting lipolysis, slimming, draining, smooth skin surface, reducing the volume of localized fat deposits, the method including applying a topical composition comprising a Nelumbo nucijera (Lotus) Extract.

The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.

The invention discloses a local fat layer thickness analyzer based on multi-electrode organism impedance measurement. The local fat layer thickness analyzer comprises the following four parts: a current excitation source, a voltage reading circuit, electrodes and data processing, the current excitation source is used for applying current to the human body tissue, the voltage reading circuit is used for measuring the voltage on the surface of the human body tissue, and the electrode is used for connecting the current excitation source, the voltage reading circuit and the human body tissue. Respectively reading voltage differences at different distances on the surface of the human tissue by using a voltage reading circuit; during data processing, a multi-electrode impedance measurement algorithm obtained through measurement fitting is substituted into a voltage reading circuit to measure a voltage difference, and the local fat layer thickness of a to-be-measured organism is obtained. Therefore, the problems caused by electrode contact impedance can be reduced, and the precision of local analysis can be improved.

Provided is an injectable composition for inducing lipolysis with less pain when injected. Since the composition has an osmolarity within an appropriate range and has a neutral pH, pain at the time of injection of the composition is very small. Also, as a large amount of drug is injected during one treatment, the lipolytic effect is excellent, and local fat removal is possible in a short period of time. The composition may be used safely without side effects. Therefore, the composition may be used in a method for inducing lipolysis.

The present invention relates to methods and compositions of vibegron or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers, or mixtures thereof for reducing body fat. The present invention further provides a method of treating localized fat, double chin disorder, benign symmetric lipomatosis, adiposis dolorosa, lipedema, and familial partial lipodystrophy in a subject by administration of the parenteral pharmaceutical compositions of vibegron. It also relates to a process for the preparation of such compositions.

The present invention relates to a composition for subcutaneous injection, containing deoxycholic acid, and a preparation method therefor. The present invention relates to a composition for non-surgical removal of localized fat deposits, the composition being micro-particles, which comprise deoxycholic acid and a biodegradable polymer, wherein the microparticles are formed such that deoxycholic acid is evenly distributed in a spherical biodegradable polymer. According to the present invention, a lipolysis effect lasts for 1 to 3 months from a single injection, a phenomenon in which surrounding tissues are destroyed during administration is prevented, and a drug release effect can be maintained at an effective amount of adipolysis concentration.

A local fat destroying method of the present invention includes: preparing a hypotonic solution; injecting the hypotonic solution into a local fat tissue using a multi-needle; expanding the fat cells while the hypotonic solution injected into the fat tissue is injected into the fat cells by an osmotic pressure phenomenon; and destroying the expanded fat cells by ultrasonic waves by applying the ultrasonic waves to the fat tissue.

A composition for displacing loose skin and removing subcutaneous deposits of fatty tissue. The composition includes effective amounts of one or more bleomycin-type drugs that are operative to cause apoptosis in localized fat cells, thus causing permanent eradication of such cells. Loose skin is likewise displaced with dense fibrous tissue produced via selective scarring induced by the active bleomycin-type drugs. The compositions are formulated as creams, lotions, gels, waxes, foams, sprays and the like for selectively applied, local topical application, and may also be administered as a conventional transdermal patch. The compositions may alternatively be formulated to be injected into the skin.

The present invention provides a composition for lipolysis, for example a pharmaceutical composition for preventing or treating obesity including localized fat deposits (LFD), comprising certain phosphocholine derivatives or pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention shows an excellent lipolytic activity as well as a uniform lipolytic activity. And also, the pharmaceutical composition of the present invention can minimize side effects such as inflammation, tissue necrosis, etc., at the administered site. In addition, the pharmaceutical composition of the present invention has excellent storage stability.

Provided is a composition and a pharmaceutical composition for reducing localized fat or promoting weight loss, wherein the composition comprises a plant extract composition comprising resveratrol and turmeric extract and a weight ratio of resveratrol and turmeric extract ranges from 1:30 to 10:1. The composition and the pharmaceutical composition are primarily administered through localized injection to inhibit the growth of fat cells and promote fat cells apoptosis to reduce adipocytes, decrease localized fat deposition, and promote weight loss, without causing inflammation or necrosis on peripheral cells or tissues to avoid severe pain, so as to avoid inflammation, damage, and pain caused by surgical liposuction or non-surgical lipolysis products such as phosphatidylcholine and sodium deoxycholate.

The present invention relates to a composition comprising glycocholic acid or taurocholic acid and phosphatidylcholine at a particular mixing ratio for reducing localized fat without side effects such as a pain, edema, necrosis of muscle cells, fibroblasts and vascular endothelial cells other than adipocytes, anesthesia of administration sites, extensive swelling, erythema, induration, paresthesia, nodule, pruritus, burning sensation, nerve injury, and dysphagia, and a method for preparing the same.The inventor has found that the effect of PPC injectable composition on fat reduction may be reduced or enhanced during its subcutaneous administration, depending on the types of solubilizing agents, especially the types of bile acids, which are combined so as to prepare a safe and stable PPC injection using insoluble PPC.The PPC injectable composition solubilized with GCA or TCA selectively reduces adipocytes without inducing necrosis of fibroblasts, muscle cells and vascular endothelial cells, thereby alleviating the known clinical side effects.

The invention describes a method and pharmaceutical compositions for subcutaneous and intracutaneous injection for reduction of localized fat deposits comprising the use of (3-sn-Phosphatidyl)-cholin as a main active and supporting ingredient either on its own, diluted or in combination with compounded agents to initiate the process of lipolysis of the adipose tissue by activating the natural metabolism process in the body. The method can be used on all excess adipose tissue of the body and face, including medical conditions that result from metabolic disorders or those originating from effects from pharmaceutical agents, in addition or apart from lifestyle conditions or other known conditions that generates the growth and expansion of fat cells to accumulate excess body fat. It is the first known effective method of use of such agents in subcutaneous and intracutaneous use that allows a cosmetic reduction of adiposity without surgical intervention. The method of the invention has made it possible to achieve satisfactory cosmetic results in one to four treatment sessions.